SCHEMBL3534013

SCHEMBL3534013

CN1CCN(Cc2ccc3nc(-c4n[nH]c5cc(Cl)ccc45)[nH]c3c2)CC1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 7/20 0.76
FLT1 P17948 3/20 0.76
GSK3B P49841 1/20 0.54
CHEK1 O14757 2/20 0.53
KDR P35968 4/20 0.52
FGFR2 P21802 3/20 0.52
FGFR3 P22607 3/20 0.52
PDGFRB P09619 1/20 0.52
HRH4 Q9H3N8 1/20 0.51
DRD2 P14416 2/20 0.50
DRD4 P21917 2/20 0.50
DRD3 P35462 2/20 0.50
HDAC3 O15379 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
ALDH1A1 P00352 1/20 0.47
CDK2 P24941 3/20 0.46
CDK4 P11802 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541844 0.88 FGFR1 (0.76) FGFR1FLT1GSK3BCHEK1KDR
SCHEMBL3535637 0.87 FGFR1 (1.00) FGFR1FLT1GSK3BCHEK1KDR
SCHEMBL3535394 0.85 FGFR1 (0.69) FGFR1FLT1GSK3BKDRFGFR2
SCHEMBL3537054 0.85 FGFR1 (0.72) FGFR1FLT1GSK3BCHEK1KDR
SCHEMBL3533608 0.85 FGFR1 (0.74) FGFR1FLT1GSK3BKDRFGFR2
SCHEMBL3536986 0.82 FGFR1 (0.72) FGFR1FLT1GSK3BKDRFGFR2
SCHEMBL3539316 0.80 FGFR1 (0.72) FGFR1FLT1GSK3BCHEK1KDR
SCHEMBL29009529 0.78 FGFR1 (0.73) FGFR1FLT1GSK3BKDRFGFR2
SCHEMBL3535030 0.78 FGFR1 (0.67) FGFR1FLT1KDRCDK2CDK4
SCHEMBL3536150 0.78 FGFR1 (0.75) FGFR1FLT1GSK3BKDRFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885GSK3B 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.